N/A N=15 Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking and Quality of Life in MS
Multiple Sclerosis
Primary: Gait Velocity: Timed Walking — 1.33; 1.4 meters/second
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=16 A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers
Healthy Volunteers · Hemophilia A
Primary: Maximum Observed Plasma Concentration (Cmax) of Emicizumab — 7.11 microgram per milliliter (μg/mL)
N/A N=223 Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Macular Degeneration
Primary: Age in Study Participants — 70.6; 77.8 years
N/A N=16 Expanded Hemodialysis Versus Online Hemodiafiltration
Dialysis Related Complication · Dialysis Hypotension · Hemodialysis-Induced Symptom
Primary: Medium Molecule Clearance — 53; 59.5 ml/min — p=0.4534
N/A N=281 Online Yoga for Individuals With Mood Disorders
Mood Disorders · Bipolar Disorder · Depression
Primary: Positive and Negative Affect Scale — 23.39; 25.38; 22.99; 15.21 units on a scale — p=0.013
Phase 1 N=23 A Study of LY3185643 and rGlucagon in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3185643 and rGlucagon — 191; 658; 1110; 2010 picogram per milliliter (pg/mL)
Phase 4 N=126 Fingolimod Effect on Cytokine and Chemokine Levels
Relapsing Remitting Multiple Sclerosis
Primary: Baseline Serum Cytokine and Chemokine Levels of Healthy Controls and RRMS Patients - ELISA — 212.26; 404.31; 1.15; 1.06 pg/ml — p=0.000
Phase 3 N=677 A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)
Alcohol Dependence
Primary: Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 12 — -12.25; -12.09; -7.91 days/month — p=0.0001
Phase 4 N=235 A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults
Chronic Weight Management
Primary: Percentage of Participants Reporting at Least One of Nine Adverse Events (AEs) of Main Interests That May Related to Serotonergic Reaction — 37.2; 42.3; 40.5 percentage…
N/A N=257 OTIVACTO Spain Non Interventional Study
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Patients With Therapeutic Success at Week 6 Approximately (Approx.) (Visit 2) — 66.2 Percentage of Patients (%)
Early Phase 1 N=34 Characteristics of Balance Control to Unexpected Loss of Balance During Standing and Walking in Post-stroke Individuals
Stroke
Primary: Change in Compensatory Step Execution Time — -119.7; -4.2 msec
N/A N=70 Does Trans-Cutaneous Electrical Nerve Stimulation (TENS) Alleviate The Pain Experienced During Bone Marrow Sampling?
Pain
Primary: Perception of Pain Will be Measured Using a Validated Numerical 0-10 Pain Scale Where 0 = no Pain and 10 = Worst Possible Pain — 5.6; 5.7; 1.9; 1.9 Numerical Pain…
N/A N=106 "Mandometer®" Study for Managing Childhood Obesity
Childhood Obesity
Primary: BMI SDS or Z-score — 3.29; 3.21; 2.93; 3.07 Z-Score
Phase 2 N=17 A Study for Participants With Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) in Part 2
N/A N=400 QuickOpt Chronic Study
Heart Failure
Primary: Percent Change in Left Ventricular End Systolic Volume (LVESV) at 12 Months Compared to Baseline — -24.69; -25.13 Percent change in LVESV